PURPOSE: The alkylating agent treosulfan exerts a high cytotoxic activity against various malignant cells. Due to limited non-hematological toxicity, treosulfan might be a promising compound in myeloablative therapy for hematopoietic transplantation in children. Since in vitro data regarding the activity of treosulfan against childhood leukemic cells are limited, we compared the effect of treosulfan and busulfan against pediatric leukemic and non-malignant cells. EXPERIMENTAL DESIGN: Both agents were tested alone and in combination with fludarabine by means of the MTT and/or a five color-flow cytometric assay. Moreover, the induction of apoptosis by treosulfan was investigated via regulation of the proteinase caspase 3. RESULTS: Treosulfan was more active against leukemic cells of 20 children as well as against 3 leukemia-derived cell lines than busulfan, with increasing IC50 values from initial diagnosis to relapse. Overall purified stem cells were most sensitive, followed by CD56+CD3- NK and CD3+ T cells. The combination of treosulfan with fludarabine resulted in a synergistic effect against leukemic cells. In malignant cells, treosulfan induced rapid cell apoptosis measured by the activation of the centrally proteinase caspase 3. CONCLUSION: Our results indicate that treosulfan has activity against pediatric leukemic cells, myeloablative potential and immunosuppressive properties suitable for conditioning regimen in childhood malignancies.
PURPOSE: The alkylating agent treosulfan exerts a high cytotoxic activity against various malignant cells. Due to limited non-hematological toxicity, treosulfan might be a promising compound in myeloablative therapy for hematopoietic transplantation in children. Since in vitro data regarding the activity of treosulfan against childhood leukemic cells are limited, we compared the effect of treosulfan and busulfan against pediatric leukemic and non-malignant cells. EXPERIMENTAL DESIGN: Both agents were tested alone and in combination with fludarabine by means of the MTT and/or a five color-flow cytometric assay. Moreover, the induction of apoptosis by treosulfan was investigated via regulation of the proteinase caspase 3. RESULTS:Treosulfan was more active against leukemic cells of 20 children as well as against 3 leukemia-derived cell lines than busulfan, with increasing IC50 values from initial diagnosis to relapse. Overall purified stem cells were most sensitive, followed by CD56+CD3- NK and CD3+ T cells. The combination of treosulfan with fludarabine resulted in a synergistic effect against leukemic cells. In malignant cells, treosulfan induced rapid cell apoptosis measured by the activation of the centrally proteinase caspase 3. CONCLUSION: Our results indicate that treosulfan has activity against pediatric leukemic cells, myeloablative potential and immunosuppressive properties suitable for conditioning regimen in childhood malignancies.
Authors: Mats Remberger; Johan Törlen; Ibrahim El Serafi; Karin Garming-Legert; Andreas Björklund; Per Ljungman; Mikael Sundin; Moustapha Hassan; Jonas Mattsson Journal: Int J Hematol Date: 2017-08-28 Impact factor: 2.490
Authors: Eneida R Nemecek; Katherine A Guthrie; Mohamed L Sorror; Brent L Wood; Kristine C Doney; Ralf A Hilger; Bart L Scott; Tibor J Kovacsovics; Richard T Maziarz; Ann E Woolfrey; Antonio Bedalov; Jean E Sanders; John M Pagel; Eileen J Sickle; Robert Witherspoon; Mary E Flowers; Frederick R Appelbaum; H Joachim Deeg Journal: Biol Blood Marrow Transplant Date: 2010-05-26 Impact factor: 5.742
Authors: Filippo Milano; Jonathan A Gutman; H Joachim Deeg; Eneida R Nemecek; Joachim Baumgart; Laurel Thur; Ann Dahlberg; Rachel B Salit; Corinne Summers; Frederick R Appelbaum; Colleen Delaney Journal: Blood Adv Date: 2020-07-28
Authors: Robert Chiesa; Joseph F Standing; Robert Winter; Zohreh Nademi; Jan Chu; Danielle Pinner; Frank Kloprogge; Susan McLellen; Persis J Amrolia; Kanchan Rao; Giovanna Lucchini; Juliana Silva; Oana Ciocarlie; Arina Lazareva; Andrew R Gennery; Bilyana Doncheva; Andrew J Cant; Sophie Hambleton; Terence Flood; Elizabeth Rogerson; Kirsty Devine; Helen Prunty; Simon Heales; Paul Veys; Mary Slatter Journal: Clin Pharmacol Ther Date: 2019-12-14 Impact factor: 6.875
Authors: Barbara Pucelik; Adam Sułek; Agnieszka Drozd; Grażyna Stochel; Mariette M Pereira; Sara M A Pinto; Luis G Arnaut; Janusz M Dąbrowski Journal: Int J Mol Sci Date: 2020-04-16 Impact factor: 5.923